The Subcommittee on Hemostasis and Malignancy of the Scientific and Standardization
Committee determined at its meeting of July 8, L992, to update the registry of clinical trials of …

The Subcommittee on Hemostasis and Malignancy of the Scientific and Standardization
Committee has established a regis try of clinical trials on coagulation-reactive drugs in …

Clinical trials of drugs that influence coagulation and fibrinolysis pathways have been
undertaken in patients with malignancy because these pathways are capable of influencing …

Because of the high risk of thrombosis, cancer patients often receive anticoagulants as
prophylaxis or treatment. It has been suggested that antithrombotic agents influence cancer …

Clinical and experimental observations have firmly established the concept of a two‐way
interaction between malignancy and the hemostatic system. On the one hand, certain tumors …

Recent evidence from both animal studies and clinical trials in human subjects has
supported the long-held notion that local fibrin deposition is important for the growth and …

A broad range of studies suggest a two-way relationship between cancer and venous
thromboembolism (VTE). Patients with cancer have consistently been shown to be at …

Acutely ill medical patients with cancer and cancer patients requiring Anticoagulants remain
the cornerstone of therapy for venous thromboembolism. In patients with cancer …

Therapeutic options for the management of venous thromboembolism (VTE) in patients with
cancer remain very limited. Although low-molecular-weight heparin monotherapy has been …

Although Trousseau1 was the earliest observer who noted the association between cancer
and thrombosis, it was Billroth2 who first described the presence of tumor cells within a …